Effects of repetitive transcranial magnetic stimulation on clinical symptoms and plasma MiR-125b,phos-phorylated Tau181 protein in patients with Alzheimer's disease
10.3969/j.issn.1001-1242.2024.02.008
- VernacularTitle:重复经颅磁刺激对阿尔茨海默病患者临床症状及血浆微小核糖核酸-125b、血浆磷酸化Tau-181蛋白的影响
- Author:
Fengxia ZHANG
1
;
Min ZHANG
;
Shanshan ZHU
Author Information
1. 武汉大学人民医院康复医学科,湖北省武汉市 430060;华中科技大学同济医学院附属同济医院康复医学科
- Keywords:
repetitive transcranial magnetic stimulation;
Alzheimer's disease;
microRNA-125b;
phosphorylated Tau181 protein
- From:
Chinese Journal of Rehabilitation Medicine
2024;39(2):196-200
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effects of repetitive transcranial magnetic stimulation(rTMS)on cognitive function,neuropsychiatric behavioral symptoms,expression of plasma microRNA-125b(miR-125b)and phosphorylated Tau181 protein(P-Tau181)of patients with Alzheimer's disease(AD). Method:Thirty-four patients with mild to moderate AD were screened and randomly divided into control group(n=16)and experimental group(n=18).The control group received cognitive training and repetitive tran-scranial magnetic pseudo-stimulation,and the experimental group received cognitive training and repetitive tran-scranial magnetic real stimulation.The magnetic stimulation intensity was 100％resting movement threshold(RMT),frequency was 10Hz.It's administered once a day,5 days a week for 4 weeks.The stimulation site were the left dorsolateral prefrontal lobe and left temporal lobe.The Addenbrooke Ⅲ cognitive examination(ACE-Ⅲ),mini-mental state scale(MMSE)and neuropsychiatric inventory(NPI)were evaluated before and af-ter treatment.The microRNA-125b expression was detected by real-time fluorescence quantitative polymerase chain reaction(qRT-PCR)and the concentration of P-Tau181 was determined by enzyme-linked immunosorbent assay(ELISA). Result:After treatment,the scores of ACE-Ⅲ,MMSE and NPI,miR-125b and P-Tau181 in the experimental group were significantly improved compared with those before treatment(P＜0.05).There was no improvement of all indexes in the control group(P＞0.05). Conclusion:rTMS improve the cognitive function and neuropsychiatric symptoms of patients with mild to mod-erate AD,which may be related to the promotion of plasma miR-125b expression and inhibition of P-Taul81 protein production by rTMS.It is worthy for clinical application.
